A citation-based method for searching scientific literature

Xue Na Goh, Michaela Su-Fern Seng, Amos Hong Pheng Loh, Achint Gupta, Kenneth Tou En Chang, Prasad Iyer. J Oncol Pharm Pract 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
Daniela Sia, Yujin Hoshida, Augusto Villanueva, Sasan Roayaie, Joana Ferrer, Barbara Tabak, Judit Peix, Manel Sole, Victoria Tovar, Clara Alsinet,[...]. Gastroenterology 2013
265
100

Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Rondell P Graham, Emily G Barr Fritcher, Ekaterina Pestova, John Schulz, Leonid A Sitailo, George Vasmatzis, Stephen J Murphy, Robert R McWilliams, Steven N Hart, Kevin C Halling,[...]. Hum Pathol 2014
139
100


Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Apinya Jusakul, Ioana Cutcutache, Chern Han Yong, Jing Quan Lim, Mi Ni Huang, Nisha Padmanabhan, Vishwa Nellore, Sarinya Kongpetch, Alvin Wei Tian Ng, Ley Moy Ng,[...]. Cancer Discov 2017
275
100

Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers: pooled data from three independent cohorts.
C B Westphalen, A Preinfalk, S Kruger, M Haas, B W Renz, M-O Riener, A Weber, T Kirchner, J Werner, V Heinemann,[...]. Clin Transl Oncol 2019
6
100

Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
Timothy Kendall, Joanne Verheij, Eugenio Gaudio, Matthias Evert, Maria Guido, Benjamin Goeppert, Guido Carpino. Liver Int 2019
64
100

Neurotrophin-3 Regulates Synapse Development by Modulating TrkC-PTPσ Synaptic Adhesion and Intracellular Signaling Pathways.
Kyung Ah Han, Doyeon Woo, Seungjoon Kim, Gayoung Choii, Sangmin Jeon, Seoung Youn Won, Ho Min Kim, Won Do Heo, Ji Won Um, Jaewon Ko. J Neurosci 2016
40
100

Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives.
Alessandro Rizzo, Angela Dalia Ricci, Simona Tavolari, Giovanni Brandi. Cancer Genomics Proteomics 2020
40
100

Trk receptors: roles in neuronal signal transduction.
Eric J Huang, Louis F Reichardt. Annu Rev Biochem 2003
100

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
918
100

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Mariangela Russo, Sandra Misale, Ge Wei, Giulia Siravegna, Giovanni Crisafulli, Luca Lazzari, Giorgio Corti, Giuseppe Rospo, Luca Novara, Benedetta Mussolin,[...]. Cancer Discov 2016
162
100

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.
D Yoshikawa, H Ojima, M Iwasaki, N Hiraoka, T Kosuge, S Kasai, S Hirohashi, T Shibata. Br J Cancer 2008
258
100

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
245
100

Molecular Pathogenesis of Cholangiocarcinoma.
Peter L Labib, George Goodchild, Stephen P Pereira. BMC Cancer 2019
57
100

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
139
100


TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M Schram, Helen H Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Amaia Arruabarrena-Aristorena,[...]. Cancer Discov 2021
7
100

Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis.
Halim Charbel, Firas H Al-Kawas. Curr Gastroenterol Rep 2011
64
100

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
Juan W Valle, Harpreet Wasan, Andre Lopes, Alison C Backen, Daniel H Palmer, Karen Morris, Marian Duggan, David Cunningham, D Alan Anthoney, Pippa Corrie,[...]. Lancet Oncol 2015
132
100

Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes.
Mina Komuta, Olivier Govaere, Vincent Vandecaveye, Jun Akiba, Werner Van Steenbergen, Chris Verslype, Wim Laleman, Jacques Pirenne, Raymond Aerts, Hirohisa Yano,[...]. Hepatology 2012
187
100

Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene.
R J Smeyne, R Klein, A Schnapp, L K Long, S Bryant, A Lewin, S A Lira, M Barbacid. Nature 1994
795
100

Infantile NTRK-associated Mesenchymal Tumors.
Jessica L Davis, Christina M Lockwood, Catherine M Albert, Karen Tsuchiya, Douglas S Hawkins, Erin R Rudzinski. Pediatr Dev Pathol 2018
56
100

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.
Loic Verlingue, David Malka, Adrien Allorant, Christophe Massard, Charles Ferté, Ludovic Lacroix, Etienne Rouleau, Nathalie Auger, Maud Ngo, Claudio Nicotra,[...]. Eur J Cancer 2017
45
100

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy,[...]. Lancet Oncol 2020
217
100

The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins.
Valeria Ranzi, Susan O Meakin, Claudia Miranda, Piera Mondellini, Marco A Pierotti, Angela Greco. Endocrinology 2003
24
100

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
109
100

Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Emiliano Cocco, Alison M Schram, Amanda Kulick, Sandra Misale, Helen H Won, Rona Yaeger, Pedram Razavi, Ryan Ptashkin, Jaclyn F Hechtman, Eneda Toska,[...]. Nat Med 2019
59
100

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
David Malka, Pascale Cervera, Stéphanie Foulon, Tanja Trarbach, Christelle de la Fouchardière, Eveline Boucher, Laetitia Fartoux, Sandrine Faivre, Jean-Frédéric Blanc, Frédéric Viret,[...]. Lancet Oncol 2014
227
100

Neoplastic Transformation of the Peribiliary Stem Cell Niche in Cholangiocarcinoma Arisen in Primary Sclerosing Cholangitis.
Guido Carpino, Vincenzo Cardinale, Trine Folseraas, Diletta Overi, Krzysztof Grzyb, Daniele Costantini, Pasquale Bartolomeo Berloco, Sabina Di Matteo, Tom Hemming Karlsen, Domenico Alvaro,[...]. Hepatology 2019
27
100

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
James P Solomon, Irina Linkov, Andrea Rosado, Kerry Mullaney, Ezra Y Rosen, Denise Frosina, Achim A Jungbluth, Ahmet Zehir, Ryma Benayed, Alexander Drilon,[...]. Mod Pathol 2020
124
100

Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma.
Hadeel Halalsheh, Mary Beth McCarville, Michael Neel, Mark Reynolds, Michael C Cox, Alberto S Pappo. Pediatr Blood Cancer 2018
11
100

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
C Marchiò, M Scaltriti, M Ladanyi, A J Iafrate, F Bibeau, M Dietel, J F Hechtman, T Troiani, F López-Rios, J-Y Douillard,[...]. Ann Oncol 2019
96
100

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Yasuhito Arai, Yasushi Totoki, Fumie Hosoda, Tomoki Shirota, Natsuko Hama, Hiromi Nakamura, Hidenori Ojima, Koh Furuta, Kazuaki Shimada, Takuji Okusaka,[...]. Hepatology 2014
242
100

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Juan Valle, Harpreet Wasan, Daniel H Palmer, David Cunningham, Alan Anthoney, Anthony Maraveyas, Srinivasan Madhusudan, Tim Iveson, Sharon Hughes, Stephen P Pereira,[...]. N Engl J Med 2010
100

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma.
M Miyamoto, H Ojima, M Iwasaki, H Shimizu, A Kokubu, N Hiraoka, T Kosuge, D Yoshikawa, T Kono, H Furukawa,[...]. Br J Cancer 2011
84
100

The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-).
Kenji Tsuchihashi, Shogo Okazaki, Mitsuyo Ohmura, Miyuki Ishikawa, Oltea Sampetrean, Nobuyuki Onishi, Hiroaki Wakimoto, Momoko Yoshikawa, Ryo Seishima, Yoshimi Iwasaki,[...]. Cancer Res 2016
46
100

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Jeeyun Lee, Se Hoon Park, Heung-Moon Chang, Jun Suk Kim, Hye Jin Choi, Myung Ah Lee, Joung Soon Jang, Hei Cheul Jeung, Jung Hun Kang, Hyun Woo Lee,[...]. Lancet Oncol 2012
271
100

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina De Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texido, Anna Degrassi,[...]. Mol Cancer Ther 2016
142
100


Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J W Valle, I Borbath, S A Khan, F Huguet, T Gruenberger, D Arnold. Ann Oncol 2016
227
100

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Darrell R Borger, Kenneth K Tanabe, Kenneth C Fan, Hector U Lopez, Valeria R Fantin, Kimberly S Straley, David P Schenkein, Aram F Hezel, Marek Ancukiewicz, Hannah M Liebman,[...]. Oncologist 2012
451
100

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Jeffrey S Ross, Kai Wang, Laurie Gay, Rami Al-Rohil, Janne V Rand, David M Jones, Hwa J Lee, Christine E Sheehan, Geoff A Otto, Gary Palmer,[...]. Oncologist 2014
240
100


The landscape of kinase fusions in cancer.
Nicolas Stransky, Ethan Cerami, Stefanie Schalm, Joseph L Kim, Christoph Lengauer. Nat Commun 2014
488
100

Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.
Boris Blechacz, Gregory J Gores. Hepatology 2008
478
100

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
467
100

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, Robin K Kelley, Sam J Lubner, Jorge Adeva, James M Cleary, Daniel V Catenacci, Mitesh J Borad, John Bridgewater,[...]. Lancet Oncol 2020
131
100

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Benjamin R Kipp, Jesse S Voss, Sarah E Kerr, Emily G Barr Fritcher, Rondell P Graham, Lizhi Zhang, W Edward Highsmith, Jun Zhang, Lewis R Roberts, Gregory J Gores,[...]. Hum Pathol 2012
138
100

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
David S Hong, Steven G DuBois, Shivaani Kummar, Anna F Farago, Catherine M Albert, Kristoffer S Rohrberg, Cornelis M van Tilburg, Ramamoorthy Nagasubramanian, Jordan D Berlin, Noah Federman,[...]. Lancet Oncol 2020
149
100

Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis.
Michael N Mavros, Konstantinos P Economopoulos, Vangelis G Alexiou, Timothy M Pawlik. JAMA Surg 2014
301
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.